Alle Studien
RekrutierungPHASE2INTERVENTIONELL

Momelotinib in VEXAS Syndrome

This research study is looking at a new drug called momelotinib for people who have VEXAS syndrome, a rare inflammatory condition, sometimes alongside a blood disorder called myelodysplastic syndrome (MDS). The main goal is to find out if momelotinib is safe and if it helps improve VEXAS symptoms and MDS features. The first part of the study will find the right dose of momelotinib. Then, more patients will receive this dose, along with their usual steroid medication. Doctors will carefully monitor participants to see how they respond to the treatment and to check for any side effects over several months.

Auf einen Blick

Status
Rekrutierung
Phase
PHASE2
Sponsor
Groupe Francophone des Myelodysplasies
Einschreibeziel
57
Starten
25 Nov 2025
Geschätzte Fertigstellung
01 Nov 2028

Worum geht es in dieser Studie?

This study is for people living with a rare condition called VEXAS syndrome. VEXAS can cause ongoing inflammation throughout the body and often requires treatment with steroids. Some people with VEXAS also have a blood disorder called myelodysplastic syndrome (MDS). We are testing a new drug, momelotinib, to see if it can help manage VEXAS symptoms and potentially improve MDS features.

Momelotinib is a type of medication that works differently from steroids. We hope it might be an effective treatment for VEXAS, especially for those who rely heavily on steroids or whose symptoms aren't fully controlled. The study is divided into two main parts. The first part is designed to safely find the best dose of momelotinib. A small number of patients will receive different doses to see which one is most tolerable.

Once the safest and most effective dose is found, more patients will be invited to join the second part of the study. Everyone in the study will continue to take their steroid medication, as determined by their doctor, alongside momelotinib. Doctors will watch closely to see if momelotinib helps improve symptoms like inflammation and if it has any positive effects on MDS. We will also be carefully monitoring for any side effects to ensure the treatment is safe.

Wichtige Erkenntnisse

  • This study is for VEXAS syndrome, with or without a blood condition (MDS).
  • It tests a new drug called momelotinib.
  • Participants will also continue taking their prescribed steroid medication.
  • The study has two parts: finding the right dose, then giving it to more patients.
  • Your health will be closely monitored with regular check-ups.
  • Sie können die Teilnahme jederzeit beenden.

Wer könnte berechtigt sein?

To be considered for this study, you must be at least 18 years old and have a confirmed diagnosis of VEXAS syndrome with a specific genetic change (UBA1 mutation). Your VEXAS symptoms should be active and currently require daily steroid treatment of at least 10mg. You might be eligible if your current treatments, including steroids, aren't fully controlling your symptoms, or if you find yourself needing higher and higher doses of steroids.

There are also some health checks you'll need to pass. For instance, your liver and kidney functions must be within certain healthy limits. If you are taking other medications that affect your immune system, you might need a short break from them before starting momelotinib. Certain growth factor treatments for blood conditions are also not allowed shortly before the study. We will check your overall health to make sure you are well enough to participate.

If you are a woman who could become pregnant, you'll need to have a negative pregnancy test and agree to use effective contraception throughout the study and for 12 weeks afterwards. If you are a man, you’ll also need to use a condom if you have sexual activity with a woman who could become pregnant. These steps are important to prevent pregnancy during the study because the effects of momelotinib on a developing baby are not known.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Sind Sie 18 Jahre oder älter?
  2. Do you have a confirmed VEXAS syndrome diagnosis with the UBA1 genetic change?
  3. Are your VEXAS symptoms active and currently require at least 10mg of steroids daily?
  4. Are your liver and kidney functions generally healthy?
  5. If you are a woman who could get pregnant, are you willing to use effective contraception?
  6. If you are a man, are you willing to use a condom if having sexual activity with a woman who could get pregnant?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If you join this study, you will first go through a screening period to check if you're a good fit. During this time, your doctor will carefully decide the right dose of steroids you need daily to manage your VEXAS symptoms. Once you start treatment, you will take momelotinib every day at a dose determined by the study, along with your prescribed steroids.

Your health will be regularly monitored with hospital visits. Doctors will evaluate your VEXAS symptoms after 4, 12, 24, and 48 weeks. If you also have MDS, those features will be checked at 12 and 24 weeks. You will continue taking momelotinib until your VEXAS symptoms worsen, you no longer respond to the treatment, or if the doctors decide, in your best interest, to stop it. If the treatment isn't helping after 24 weeks at the optimal dose, it will be stopped. The study involves regular check-ups and medication, potentially for many months, but you can choose to leave the study at any time.

Potenzielle Risiken und Vorteile

Taking part in this study may offer potential benefits, such as receiving a new and experimental treatment (momelotinib) that might help control your VEXAS symptoms and potentially improve MDS features, especially if your current treatments aren't fully effective. However, as with any new medication, there are potential risks and side effects that we don't fully know yet. These will be closely monitored, and your study doctor will discuss what is currently known. Your health will be carefully watched throughout the study. Remember, joining this study is completely voluntary, and you have the right to withdraw at any time, for any reason, without it affecting your usual medical care.

Standorte (11)

  • CHU d'Angers - Service des Maladies du sang
    Verifizierte Postleitzahl
    Angers, Frankreich· Noch nicht rekrutiert
  • CHU Estaing - Service d'Hématologie Clinique
    Verifizierte Postleitzahl
    Clermont-Ferrand, Frankreich· Noch nicht rekrutiert
  • Hôpital Claude Huriez - Service de Médecine Interne
    Verifizierte Postleitzahl
    Lille, Frankreich· Noch nicht rekrutiert
  • CHU Nantes - Hôtel Dieu - Service d'Hématologie Clinique
    Verifizierte Postleitzahl
    Nantes, Frankreich· Noch nicht rekrutiert
  • Hôpital Saint Louis - Service hématologie séniors
    Verifizierte Postleitzahl
    Paris, Frankreich· Noch nicht rekrutiert
  • Hôpital Saint-Antoine - Service de Médecine Interne
    Verifizierte Postleitzahl
    Paris, Frankreich· Noch nicht rekrutiert
  • CHU de Haut-Lévèque - Centre F. Magendie - Service des Maladies du sang
    Verifizierte Postleitzahl
    Pessac, Frankreich· Noch nicht rekrutiert
  • CH Lyon sud - Service d'Hématologie Clinique
    Verifizierte Postleitzahl
    Pierre-Bénite, France· Rekrutierung
  • Hôpital Pontchaillou Service d'hématologie clinique et service de médecine interne
    Verifizierte Postleitzahl
    Rennes, France· Noch nicht rekrutiert
  • IUCT Oncopole Département d'hématologie / Unité de médecine interne
    Verifizierte Postleitzahl
    Toulouse, Frankreich· Noch nicht rekrutiert
  • CHU de Tours - Hôpital Bretonneau - Service de Médecine Interne
    Verifizierte Postleitzahl
    Tours, Frankreich· Noch nicht rekrutiert

Häufige Fragen

What is VEXAS syndrome?

VEXAS syndrome is a rare condition that causes ongoing inflammation in different parts of the body, often needing steroid treatment.

What is momelotinib?

Momelotinib is a new experimental drug being tested in this study to see if it can help treat VEXAS syndrome and associated blood problems.

Will I still take my usual steroids?

Yes, all patients in the study will continue to take their daily steroid medication as prescribed by their doctor, alongside momelotinib.

Wie lange wird die Studie für mich dauern?

The study's length varies by individual; you'll take momelotinib until your symptoms worsen, you stop responding, or your doctor decides to stop it.

Kann ich die Studie jederzeit verlassen?

Yes, you are free to leave the study at any point, for any reason, and this will not affect your future medical care.

Wie Sie mehr erfahren können

Maël HEIBLIG, MD

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Interessiert daran, teilzunehmen?

Registrieren Sie Ihr Interesse

Teilen Sie Ihre Details und das Forschungsteam für "Momelotinib in VEXAS Syndrome… wird Sie kontaktieren, wenn Sie möglicherweise infrage kommen. Sprechen Sie immer mit Ihrem Hausarzt, bevor Sie zustimmen, teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.